{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T20:48:56Z","timestamp":1793134136370,"version":"4.5.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,6,4]],"date-time":"2021-06-04T00:00:00Z","timestamp":1622764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Four clinical active surveillance trials including LORIS, COMET, LORD and LORETTA, are being conducted to assess whether women with low-risk ductal carcinoma in situ can safely avoid surgery. The present study aimed to determine the rate of upstaging to invasive cancer among patients with a preoperative diagnosis of ductal carcinoma in situ and to evaluate the incidence of upstaging in patients meeting the eligibility criteria for four active surveillance clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The present study initially enrolled 180 patients with 183 calcifications who received the diagnosis of ductal carcinoma in situ by biopsy. Patients were classified as eligible for four clinical trials according to the respective inclusion criteria.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In total, 152 patients with 155 calcifications were analyzed. Of these, 32 (21%) were upstaged to invasive disease based on the final pathological analysis of surgical specimens. Of the 152 patients, 53 (35%), 90 (59%), 24 (16%) and 34 (22%) met the eligibility criteria for the LORIS, COMET, LORD and LORETTA trial, respectively. Among patients with low-risk ductal carcinoma in situ, 10 (19%), 14 (16%), 6 (25%) and 4 (12%) patients were upstaged to invasive disease in LORIS, COMET, LORD and LORETTA, respectively. The upstaging to pT1b or higher rates were 2% (1\/53), 3% (3\/90), 0% (0\/24) and 3% (1\/34) in LORIS, COMET, LORD and LORETTA, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The upstaging rate in patients eligible for the clinical active surveillance trials was 12\u201325%. Although the rate of upstaging to pT1b or higher was low, further studies are required to determine the rates of upstaging to invasive cancer and the risk factors among patients with low-risk ductal carcinoma in situ.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyab082","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T19:11:37Z","timestamp":1621365097000},"page":"1219-1224","source":"Crossref","is-referenced-by-count":18,"title":["Surgical upstaging rates in patients meeting the eligibility for active surveillance trials"],"prefix":"10.1093","volume":"51","author":[{"given":"Naoko","family":"Iwamoto","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyako","family":"Nara","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichiro","family":"Horiguchi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Aruga","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,4]]},"reference":[{"key":"2021080204311820600_ref1","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","article-title":"Ductal carcinoma in situ: to treat or not to treat, that is the question","volume":"121","author":"Seijen","year":"2019","journal-title":"Br J Cancer"},{"key":"2021080204311820600_ref2","doi-asserted-by":"publisher","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","article-title":"Addressing overtreatment of screen detected DCIS; the LORIS trial","volume":"51","author":"Francis","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021080204311820600_ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026797","article-title":"The COMET (comparison of operative versus monitoring and endocrine therapy) trial: a phase lll randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)","volume":"9","author":"Hwang","year":"2019","journal-title":"BMJ Open"},{"key":"2021080204311820600_ref4","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","article-title":"Feasibility of a prospective, randomized, open-label, international multicentre, phase lll, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ-The LORD study","volume":"51","author":"Elshof","year":"2015","journal-title":"Eur J Cancer"},{"key":"2021080204311820600_ref5","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/jjco\/hyx059","article-title":"Current approach and future perspective for ductal carcinoma in situ of the breast","volume":"47","author":"Kanbayashi","year":"2017","journal-title":"Jpn J Clin Oncol"},{"key":"2021080204311820600_ref6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS603","article-title":"The international collaboration of active surveillance trials for low-risk DCIS (LORIS, LORD, COMET, LORETTA)","volume":"37","author":"Kanbayashi","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021080204311820600_ref7","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1245\/s10434-017-6018-9","article-title":"Surgical upstaging rates for vacuum assisted biopsy proven DCIS: implications for active surveillance trials","volume":"24","author":"Grimm","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2021080204311820600_ref8","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.ejso.2013.09.028","article-title":"Concordance between vacuum assisted biopsy and postoperative histology: implications for the proposed low risk DCIS trial (LORIS)","volume":"39","author":"Soumian","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"2021080204311820600_ref9","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1245\/s10434-017-5927-y","article-title":"A validated nomogram to predict upstaging of ductal carcinoma in situ to invasive diseases","volume":"24","author":"Jakub","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2021080204311820600_ref10","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1245\/s10434-016-5268-2","article-title":"Do LORIS trial eligibility criteria identify a ductal carcinoma in situ (DCIS) patient population at low risk of upgrade to invasive carcinoma?","volume":"23","author":"Pilewskie","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2021080204311820600_ref11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1148\/radiol.11102368","article-title":"Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer","volume":"260","author":"Brennan","year":"2011","journal-title":"Radiology"},{"key":"2021080204311820600_ref12","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41416-018-0276-6","article-title":"A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers","volume":"119","author":"Meurs","year":"2018","journal-title":"Br J Cancer"},{"key":"2021080204311820600_ref13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-019-05362-1","article-title":"Reliability of preoperative breast biopsies showing ductal carcinoma in situ and implications for non-operative treatment: a cohort study","volume":"178","author":"Mannu","year":"2019","journal-title":"Breast cancer Res Treat"},{"key":"2021080204311820600_ref14","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ejso.2019.01.015","article-title":"Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score","volume":"45","author":"Marques","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2021080204311820600_ref15","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/bjs.9337","article-title":"Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast","volume":"100","author":"Lee","year":"2013","journal-title":"Br J Surg"},{"key":"2021080204311820600_ref16","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamasurg.2017.2181","article-title":"Factors associated with underestimation of invasive cancer in patients with ductal carcinoma in situ: precautions for active surveillance","volume":"152","author":"Chavez de Paz Villanueva","year":"2017","journal-title":"JAMA Surg"},{"key":"2021080204311820600_ref17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/cas.12381","article-title":"Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ","volume":"105","author":"Osako","year":"2014","journal-title":"Cancer Sci"},{"key":"2021080204311820600_ref18","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s10549-006-9167-2","article-title":"Is there a role of sentinel lymph node biopsy in ductal carcinoma in situ?: analysis of 587 cases","volume":"98","author":"Goyal","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"2021080204311820600_ref19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jso.24037","article-title":"A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast","volume":"112","author":"Kondo","year":"2015","journal-title":"J Surg Oncol"},{"key":"2021080204311820600_ref20","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1245\/s10434-013-3239-4","article-title":"Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy","volume":"21","author":"Chin-Lenn","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2021080204311820600_ref21","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10549-016-3783-2","article-title":"Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy","volume":"156","author":"Roozendaal","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2021080204311820600_ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-021-01225-0","article-title":"Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study","author":"Tanaka","year":"2021","journal-title":"Breast Cancer"},{"key":"2021080204311820600_ref23","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1200\/JCO.2006.09.2775","article-title":"American society of clinical oncology\/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer","volume":"25","author":"Wolff","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021080204311820600_ref24","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J Clin Oncol"},{"key":"2021080204311820600_ref25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"2021080204311820600_ref26","doi-asserted-by":"publisher","first-page":"712","DOI":"10.2214\/AJR.17.19244","article-title":"Patient selection for ductal carcinoma in situ observation trials: are the lesions truly low risk?","volume":"211","author":"Patel","year":"2018","journal-title":"AJR Am J Roentgenol"},{"key":"2021080204311820600_ref27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1038\/s41416-020-01152-5","article-title":"Pathological features of 11337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane project","volume":"124","author":"Shaaban","year":"2021","journal-title":"Br J Cancer"},{"key":"2021080204311820600_ref28","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s12253-019-00760-8","article-title":"Grading ductal carcinoma in situ (DCIS) of the breast \u2013 what\u2019s wrong with it?","volume":"26","author":"Cserni","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"2021080204311820600_ref29","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1245\/s10434-017-6174-y","article-title":"Confusion over differences in registration and randomization criteria for the LORIS (Low-Risk DCIS) trial","volume":"24","author":"Rea","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"2021080204311820600_ref30","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyaa235","article-title":"Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study","author":"Tsuda","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"2021080204311820600_ref31","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jama.2015.1405","article-title":"Diagnostic concordance among pathologists interpreting breast biopsy specimens","volume":"313","author":"Elmore","year":"2015","journal-title":"JAMA"},{"key":"2021080204311820600_ref32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ejca.2017.04.013","article-title":"The diagnostic challenge of low-grade ductal carcinoma in situ","volume":"80","author":"Onega","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021080204311820600_ref33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamasurg.2017.2181","article-title":"Factors associated with underestimation of invasive cancer in patients with ductal carcinoma in situ: precautions for active surveillance","volume":"152","year":"2017","journal-title":"JAMA Surg"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/8\/1219\/39503302\/hyab082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/51\/8\/1219\/39503302\/hyab082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T04:31:42Z","timestamp":1627878702000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/51\/8\/1219\/6292254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,4]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,6,4]]},"published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyab082","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8]]},"published":{"date-parts":[[2021,6,4]]}}}